Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRINITY phase 2 study of rovalpituzumab tesirine in relapsed or refractory DLL3-expressing small cell lung cancer
2015-004506-42Phase 2Completed
- Sponsor
- Stemcentrx
- Start
- Jan 2016
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rovalpituzumab tesirine in small cell lung cancer (SCLC), sponsored by Stemcentrx. Primary endpoint: Objective response rate. Started Jan 2016; status: completed.
02
Drugs
rovalpituzumab tesirine
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2015-004506-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004506-42.